Ignite Creation Date:
2025-12-25 @ 4:03 AM
Ignite Modification Date:
2026-01-10 @ 12:51 PM
Study NCT ID:
NCT01434602
Status:
COMPLETED
Last Update Posted:
2022-06-01
First Post:
2011-09-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
Sponsor:
National Cancer Institute (NCI)
Organization:
Organization Data
Organization:
Class:
NIH
Study ID:
160011
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
NIH
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None